File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: CYP3A4-mediated pharmacokinetic interactions in cancer therapy

TitleCYP3A4-mediated pharmacokinetic interactions in cancer therapy
Authors
Tian, DHu, Z
KeywordsAnticancer drugs
Cytochromes P450 (CYP) enzymes
Drug-drug interactions
Pharmacokinetics
Issue Date2014
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdm/index.htm
Citation
Current Drug Metabolism, 2014, v. 15 n. 8, p. 808-817 How to Cite?
DOI: http://dx.doi.org/10.2174/1389200216666150223152627
AbstractCytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.
Persistent Identifierhttp://hdl.handle.net/10722/215632
ISSN
1389-2002
2021 Impact Factor: 3.408
2020 SCImago Journal Rankings: 0.667
ISI Accession Number ID
WOS:000350280800005

 

DC FieldValueLanguage
dc.contributor.authorTian, D-
dc.contributor.authorHu, Z-
dc.date.accessioned2015-08-21T13:33:32Z-
dc.date.available2015-08-21T13:33:32Z-
dc.date.issued2014-
dc.identifier.citationCurrent Drug Metabolism, 2014, v. 15 n. 8, p. 808-817-
dc.identifier.issn1389-2002-
dc.identifier.urihttp://hdl.handle.net/10722/215632-
dc.description.abstractCytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.-
dc.languageeng-
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdm/index.htm-
dc.relation.ispartofCurrent Drug Metabolism-
dc.subjectAnticancer drugs-
dc.subjectCytochromes P450 (CYP) enzymes-
dc.subjectDrug-drug interactions-
dc.subjectPharmacokinetics-
dc.titleCYP3A4-mediated pharmacokinetic interactions in cancer therapy-
dc.typeArticle-
dc.identifier.emailTian, D: tiandd@hku.hk-
dc.identifier.doi10.2174/1389200216666150223152627-
dc.identifier.pmid25705904-
dc.identifier.scopuseid_2-s2.0-84928395247-
dc.identifier.hkuros246031-
dc.identifier.volume15-
dc.identifier.issue8-
dc.identifier.spage808-
dc.identifier.epage817-
dc.identifier.isiWOS:000350280800005-
dc.publisher.placeNetherlands-
dc.identifier.issnl1389-2002-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats